Meridia Pediatric Adverse Events Will Get Continued Monitoring
This article was originally published in The Pink Sheet Daily
FDA notes that only one pediatric adverse case report was recorded and additional surveillance is necessary for a more meaningful analysis.
You may also be interested in...
Incidence of events with Sparlon is higher than for placebo but exposure in patients is also greater, FDA summary of clinical adverse events states.
Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.